肿瘤细胞治疗研究
ALL SOURCES
Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS tumors: Results of the completed BrainChild02 phase 1 clinical
颅内输注 EGFR806-CAR-T 细胞在测试剂量下可耐受，最佳反应为疾病稳定。EGFR 是针对儿童脑肿瘤，特别是高级别胶质瘤的细胞治疗的潜在有用靶点。
Locoregional and systemic adoptive cellular therapies for pediatric brain tumors: a systematic review of CAR‑T, TCR‑engineered T cells, and NK cell st
检索获得 324 条记录；去除 103 条重复记录；筛选 221 篇标题和摘要；审阅 180 篇全文；由两名独立评价者提取 34 项研究。
CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.
CAR-T 细胞（CAR-T 细胞）是经过工程化改造的细胞，表达针对特定肿瘤抗原（TA）的嵌合抗原受体（CAR），从而能够识别并清除癌细胞。
Identification of molecularly targeted therapy-induced immunopeptidome in diffuse midline glioma (DMG).
MTX-241F 改变了胶质瘤免疫肽组，揭示 H2B1K、脑富集免疫肽以及治疗诱导的免疫肽是免疫可见的靶点。
Latest Advancements in the Management of H3K27M-Mutant Diffuse Intrinsic Pontine Glioma: A Narrative Review.
尽管近年来在弥漫性内生性桥脑胶质瘤（DIPG）的放疗方面取得了进展，但该病的预后仍然很差，凸显出需要新的治疗策略来改善结局。
Pediatric Hemispheric High-Grade Gliomas and H3.3-G34 Mutation: A Review of the Literature on Biological Features and New Therapeutic Strategies.
近 50% 的 pHGG 存在编码组蛋白 3 的基因突变，包括携带 H3.3-G34 突变的亚型。
Review: therapeutic approaches for circadian modulation of the glioma microenvironment.
高级别胶质瘤是恶性脑肿瘤，因其特性而难以治疗；它们在成人中生长迅速，并侵袭性地穿过脑组织，且对放化疗产生耐药性。
Locoregional CAR T Cells for the Treatment of CNS Tumors in Children: Investigational Drug Service Pharmacy Activities.
随着过继性免疫治疗领域的不断发展，并持续为致命性 CNS 恶性肿瘤患者带来希望，关注改进 CAR-T 细胞递送的准备步骤至关重要。
共 8 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
